Venux

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venux

What is Venux? Quick Facts and Identity

This section provides a factual overview of the identity, composition, and high-level classification of Venux, strictly excluding details on dosage, specific diseases it treats, or administration instructions.

Property Description
Active ingredient Sildenafil (as Sildenafil Citrate)
Form Oral tablet (film-coated)
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
Common use Supports enhanced localized blood flow
Origin Synthetic compound

What Type of Medicine is Venux?

Venux is a prescription-only medication whose active ingredient, Sildenafil, is classified as a Phosphodiesterase type 5 (PDE5) inhibitor. Venux is characterized by its formulation as a single-ingredient product designed for systemic action. As a PDE5 inhibitor, Sildenafil is noted for its ability to modulate circulatory responses. The oral tablet form and prescription-only status are distinctive features that define its place in the market compared to over-the-counter or topical options.


Composition and Origin of Venux

The core active substance in Venux is Sildenafil Citrate, a synthetic chemical compound derived from the Pyrazolo-pyrimidinone class. Venux is consistently manufactured for systemic delivery as an oral tablet which is film-coated. This physical preparation allows the active Sildenafil Citrate to be absorbed into the bloodstream via oral administration, utilizing a solid oral matrix of excipients for stability and reliable dosing. Its specific formulation is intended for adult patient groups requiring this class of medication.


General Purpose of the PDE5 Inhibitor Class

The primary function of the PDE5 inhibitor class is to promote the relaxation and widening of blood vessels, which facilitates enhanced localized blood flow. This is achieved by the drug's action of inhibiting the PDE5 enzyme, which naturally breaks down the messenger molecule, cGMP. By protecting cGMP, Venux supports the body's natural signaling pathway that leads to vascular smooth muscle relaxation and subsequent vasodilation. A typical, neutral use scenario for this drug class involves supporting physiological functions that rely on robust localized circulation in the target area.

Regulatory References

  1. NIH MedlinePlus Drug Information on Sildenafil

What side effects are possible with Venux?

Possible Side Effects and Safety Information

The safety profile of Venux (Sildenafil) is structured by regulatory authorities based on the frequency and the System Organ Class (SOC) affected. These classifications establish the risk patterns documented in official labeling, strictly defining the medicine’s expected adverse reactions and safety constraints.


Documented Adverse Reactions

Adverse reactions are classified according to regulatory frequency standards. The most frequently reported effect is Headache, which is classified as Very Common (may affect more than 1 in 10 users). Reactions classified as Common (may affect up to 1 in 10 users) include Flushing (vasodilation), Dyspepsia (indigestion), Nasal Congestion, and Visual Disturbances.

Uncommon effects, such as a rash or vomiting, are also listed. Effects are generally described as transient and dose-related.

System Organ Class Example Reactions (Common)
Nervous System Headache, Dizziness
Vascular Disorders Flushing
Eye Disorders Visual Disturbances
Gastrointestinal Dyspepsia

Serious Safety Considerations and Constraints

Official labeling highlights rare but serious adverse reactions, including Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a condition leading to sudden loss of vision, and Priapism, a prolonged erection lasting more than four hours.

Regulatory documents define specific constraints for use. The medicine is strictly contraindicated for patients concurrently taking nitrates in any form. Safety considerations also exist for specific patient groups, including those with severe renal impairment or severe hepatic impairment, where caution and potential dose adjustment are required.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory authorities require that immediate medical attention be sought for any suspected overdose of Venux (Venlafaxine). This is due to the potential for severe, life-threatening manifestations documented in official prescribing information.

Overdose cases are officially reported to include a range of symptoms, primarily affecting the Central Nervous System and Cardiovascular System. Documented manifestations commonly include changes in consciousness such as somnolence, convulsions (seizures), tachycardia (increased heart rate), and hypotension (low blood pressure). ECG abnormalities, specifically QRS prolongation, have also been reported.

Documented Severe Outcomes

Severe or fatal outcomes have occurred, particularly when Venux is co-ingested with alcohol or other psychoactive medicinal products. Officially documented severe complications include Serotonin Syndrome, progression to coma, and death.

Management and Emergency Actions

The official management approach is strictly symptomatic and supportive. Regulatory documents confirm that no specific antidote is known for Venlafaxine overdose. Therefore, intensive medical monitoring, including continuous ECG monitoring, is recommended for symptomatic patients due to the cardiac risks. Urgent medical help must be contacted immediately for any potential overdose scenario.

Therapeutic Uses of Venux

Venux (Venlafaxine) is a prescription medication commonly used across therapeutic domains where additional symptomatic support is needed. It may be applied in addressing conditions where functional stability becomes affected, and plays a role in managing symptoms related to systemic imbalance and heightened physiological activity. Venux is considered relevant for easing the symptoms that create noticeable physiological strain.

The main therapeutic uses address conditions involving episodic or fluctuating manifestations. These commonly include: Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). Venux is commonly used to help with symptom clusters that may become intense or disruptive, and may assist with maintaining functional stability during phases of increased distress or discomfort.

“This medication supports patients during difficult episodes by easing distress and contributing to easing the overall symptom load.”

Venux is often used when symptoms intensify and supportive relief is needed. It contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Quick Fact: Used in management of Symptom Clusters

Eligibility and Restrictions for Use

Who Can and Cannot Use Venux?

Venux (Sildenafil) eligibility is strictly defined by regulatory health authorities based on patient population, concurrent medication, and existing health status. The criteria distinguish between groups allowed use, those restricted, and those absolutely prohibited.

Absolute Contraindications (Must Not Use): Use is strictly contraindicated if you are taking any form of organic nitrate (such as nitroglycerin) or certain other medications like Guanylate Cyclase stimulators. The medicine is also prohibited for individuals with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), known hypersensitivity to sildenafil, severe cardiovascular conditions (e.g., recent stroke or heart attack within six months), or severe hepatic impairment for the Erectile Dysfunction (ED) indication.

Age and Condition Restrictions: Venux is generally allowed for adults (ge 18 years). It is not indicated for use by women for the ED formulation. Individuals who are older adults (ge 65 years) or who have severe renal or hepatic impairment (not severe) may require use under restricted conditions, often including the consideration of a lower initial dose for the ED indication. Use in children for Pulmonary Arterial Hypertension (PAH) is subject to specific safety warnings and not recommended in some jurisdictions.

What should I know about interactions with other medicines?

The official regulatory profile for Venux (Venlafaxine) establishes specific restrictions and constraints regarding co-administration with other substances.

Certain combinations are classified as contraindicated, including:

  • Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders.
  • Linezolid and Intravenous Methylene Blue.

Mandatory timing rules apply: at least 14 days must elapse after discontinuing a psychiatric MAOI before initiating Venux, and at least 7 days must elapse after discontinuing Venux before initiating an MAOI.

Interactions also stem from two primary mechanisms. Pharmacodynamic reinforcement occurs with other serotonergic agents (e.g., Triptans, Tramadol, St. John's Wort), which increases the potential for Serotonin Syndrome. Co-administration with drugs that interfere with hemostasis (e.g., NSAIDs, Aspirin) is documented to increase the risk of bleeding events. Alcohol should be avoided due to the potential for increased sedation.

The profile documents pharmacokinetic alterations. Strong CYP3A4 inhibitors (e.g., Ketoconazole, Cimetidine) significantly increase Venlafaxine exposure by inhibiting metabolic clearance. Conversely, Venlafaxine has been shown to reduce the clearance of co-administered drugs like Haloperidol, thereby increasing its exposure. The Cimetidine interaction is noted as potentially more pronounced in elderly patients or those with hepatic dysfunction.

Mechanism of Action

How Venux Works: Mechanism of Action

The mechanism of Venux (Sildenafil) is defined by its precise interaction with a specific enzyme system, which results in localized modulation of vascular smooth muscle tone.


Targeted Inhibition of the PDE5 Enzyme

Venux acts as a highly selective competitive inhibitor of the Phosphodiesterase type 5 ( PDE5) enzyme. This enzyme is naturally present in certain vascular smooth muscle cells and breaks down the crucial signaling molecule, cyclic Guanosine Monophosphate ( cGMP). By blocking PDE5, Sildenafil prevents cGMP degradation. This action results in the protection of the second messenger, thereby sustaining the physiological cascade.


Sustaining the NO-cGMP Signal for Vascular Relaxation

The drug's mechanism is intrinsically dependent on the Nitric Oxide ( NO) signaling pathway. Sildenafil potentiates the effect of NO (which is released upon physiological stimulus) by allowing cGMP to accumulate. The resulting increased cGMP concentration triggers a reduction in intracellular calcium levels ( Ca^2+), leading directly to the relaxation of vascular smooth muscle. This ultimately causes localized vasodilation and increased blood flow in the target area. This mechanism is physiologically constrained; the drug’s action is contingent upon the initial NO signal being present.

Dosage and Administration Information

How Venux is used: Official Administration Guidelines

The administration of Venux (Sildenafil) is defined by two primary protocols: on-demand use and fixed-schedule use. The official routes of administration include the oral route, available as tablets or a reconstituted suspension, and the intravenous (IV) route, which is generally used in clinical settings for patients temporarily unable to take the medicine by mouth.

Usage is fundamentally structured by the regimen required. On-Demand Use involves an initial dose of 50 mg, adjustable within a 25 mg to 100 mg range, and must not exceed a maximum frequency of once per day. In contrast, the Fixed-Schedule Regimen requires continuous dosing, typically starting at 20 mg and administered three times a day (TID), with doses spaced approximately 4–6 hours apart.

Regimen Type Standard Dosing Range Frequency Pattern
On-Demand Use Initial dose of 50 mg, adjustable from 25 mg up to 100 mg. Maximum of once per day.
Fixed-Schedule Use Standard dose of 20 mg, up to 80 mg TID. Three times a day (TID).

Regarding administration context, the oral tablets may be taken with or without food. A lower starting dose of 25 mg is considered for the on-demand regimen in specific populations, including older adults (aged 65 years and over) and individuals with severe renal impairment or hepatic impairment. Formulations like the oral suspension require careful reconstitution and the use of a calibrated measuring device to ensure accurate delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Phase Clinical Trials (Phase I/II)

Early phase trials investigated the drug's molecular activity, with some participants documenting observations regarding common symptoms like fatigue and splenomegaly. These initial studies focused primarily on establishing the dose range and characterizing potential side effects. Toxicity findings informed the parameters for dose selection for later-stage trials.


Efficacy in Chronic Myeloid Leukemia (CML)

Research has evaluated whether the drug may affect clinical outcomes in patients with Chronic Myeloid Leukemia (CML), examining the impact on the number of cancer cells. Studies have investigated whether this treatment is associated with control of disease progression.

  • Newly Diagnosed CML: Research has explored the drug's role in the treatment sequence for newly diagnosed patients. Research has compared the treatment against older Tyrosine Kinase Inhibitors (TKIs) to evaluate the rate of major molecular response.
  • Resistant or Intolerant CML: Studies have been conducted to evaluate the use of the drug in patients who experienced difficulty or inadequate response with prior TKI treatments. The primary focus of these trials was evaluating molecular and cytogenetic response rates.

Combination Therapies

Studies have compared the combination of this drug with existing chemotherapy against monotherapy to evaluate potential differences in overall survival rates. Other research has explored the feasibility of combining the drug with immune checkpoint inhibitors, focusing on safety and preliminary activity profiles.


Specific Populations and Safety

Research has examined the effects of the drug in elderly patients and those with mild kidney impairment. Trial protocols detailed the monitoring for adverse events. Dosing and regimen were defined by the trial protocols in the reviewed research. No studies suggesting off-label uses were included in this overview.

Key Studies & References NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myeloid Leukemia - Provides context for treatment sequence and comparisons (Version 1.2017 or similar)

Frequently Asked Questions (FAQ)

Common questions about Venux (FAQ)


Q: What is the main reason a doctor might prescribe Venux?

A: Official regulatory documents indicate that the active ingredient in Venux, Sildenafil, is prescribed for two main authorized uses. These uses include the treatment of Erectile Dysfunction (ED) and the management of Pulmonary Arterial Hypertension (PAH), which is high blood pressure in the arteries of the lungs.


Q: Is Venux a long-term or short-term medication?

A: The required duration of use depends entirely on the underlying condition being addressed. Official documents describe use on an on-demand basis for conditions like ED, meaning it is taken only as needed. However, for chronic conditions such as PAH, Venux is often used on a fixed-schedule and may be considered a long-term medication.


Q: How quickly can someone expect Venux to start working?

A: Regulatory information states that the highest concentration of the drug in the blood, known as the Cmax, is typically reached between 30 and 120 minutes (median 60 minutes) after taking an oral dose on an empty stomach. This measure reflects when the active ingredient is fully absorbed by the body.


Q: Does Venux have to be taken forever, or can I stop taking it?

A: Venux should only be taken for as long as your prescribed condition requires. For short-term or on-demand use, it is taken only when needed. If you are using the fixed-schedule regimen for a chronic condition, the duration of therapy may be long-term, and stopping or changing this medication generally requires the direction of a healthcare professional.


Q: Does Venux affect sleep patterns?

A: Official reports on adverse reactions list insomnia, or difficulty sleeping, as a common side effect. In clinical studies, this effect was reported by between 1% and 10% of users. If changes in sleep patterns are experienced, the patient information advises consulting a healthcare professional.


Q: Can Venux make you gain or lose weight?

A: Official regulatory documents list changes in weight as a potential adverse reaction for some approved indications. Specifically, increased weight and fluid retention have been reported as common side effects, affecting between 1% and 10% of people in clinical studies for those indications.


Q: What happens if I miss a dose of Venux?

A: For the fixed-schedule regimen, official product information includes guidance on how to manage a missed dose. This guidance states that if a dose is missed, it should be taken as soon as possible, but advises against taking double or extra doses to compensate.


Q: Does taking Venux impact my ability to drive or operate machinery?

A: Official information indicates that studies on the effects on driving have not been formally performed, but common side effects should be considered. Since dizziness and visual disturbances are known common side effects, these symptoms could potentially impair one’s ability to safely drive or operate machinery.


Q: Is Venux a controlled substance?

A: According to official drug scheduling information, the active ingredient in Venux, Sildenafil, is not classified as a controlled substance by the DEA (Drug Enforcement Administration). It is categorized as a prescription-only medication.


Q: Is it possible to become dependent on Venux?

A: Sildenafil is not classified as a controlled substance. The official product labeling does not document physical addiction or dependence.


Q: How is Venux eliminated from the body?

A: The body primarily clears the active ingredient through metabolism in the liver. Regulatory information states that the resulting metabolites are mainly excreted in the feces, accounting for about 80% of an oral dose, and to a lesser extent, in the urine.


Q: Are there any restrictions on activity level while taking Venux?

A: Regulatory documents include a warning that sexual activity itself may put extra strain on the heart. Patients should be assessed by their healthcare professional regarding their readiness for sexual activity, especially if they have underlying heart conditions.


Q: How long does the effect of a single dose of Venux typically last?

A: Official study data indicates that the effects of the active ingredient in Venux have been documented to last for up to 4 hours after administration. It is noted that the level of response may diminish when comparing the 4-hour mark to the peak response observed earlier.


Q: Can Venux affect my mood or cause anxiety?

A: Yes, official reports on adverse reactions list anxiety as a common side effect. This means that anxiety was reported by between 1% and 10% of users in clinical studies for some indications.


Q: Are there specific symptoms that require immediately stopping Venux?

A: Regulatory warnings highlight that certain serious reactions, such as a sudden decrease or loss of vision or hearing or a prolonged erection lasting more than 4 hours (Priapism), require immediate medical attention.


Q: Is there a generic version of Venux available?

A: Yes. The active ingredient in Venux is Sildenafil, which is the generic name for the drug. The active ingredient is commonly available as a generic product.


Q: Does Venux contain any allergens like gluten or lactose?

A: The official product label provides a list of inactive ingredients, which are the non-active components of the tablet. Information on specific excipients, such as lactose or gluten, can be found on the full list of ingredients in the product labeling.


Q: Can I use Venux if I have a history of seizures?

A: Post-marketing safety reports documented in official regulatory sources indicate that seizures and recurrence of seizures have been reported with the use of Sildenafil. The safety profile indicates that patients should be assessed for underlying seizure risk factors by a healthcare professional.


Q: What is the shelf life of Venux tablets?

A: The shelf life of Venux tablets is defined by the manufacturer and is stated in the official product information. Sildenafil tablets typically have an approved shelf life of two years (24 months) from the date they were manufactured.

How should Venux be stored and disposed of?

How to Store and Dispose of Venux?

The storage and disposal requirements for Venux (Venlafaxine Extended-Release Capsules) are established in official regulatory documents to ensure product stability and safety.

Official Storage Conditions

Venux must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with protection from excessive heat outside this range. The product must be kept in a tightly closed container and protected from moisture and light to maintain its integrity.

Safety and Disposal Rules

All medication must be stored out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired Venux should be taken to an authorized drug take-back program. If a take-back program is unavailable, it should be mixed with an unpalatable substance (like coffee grounds), sealed in a bag, and discarded in the household trash. The medication should not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venux found in:

A-Z Index: